

Pablo R. Moya, PhD

Dr. Pablo R. Moya

Laboratorio de Neurogenética
Instituto de Fisiología, Facultad de Ciencias
Universidad de Valparaíso

ANTECEDENTES PERSONALES

Nombre Completo: Pablo Ricardo Moya Vera

Fecha de Nacimiento: 09/09/1975

Correo electrónico: pablo.moya@uv.cl

TITULOS DE GRADO Y POSGRADO

- 2001-2005 **Doctor en Ciencias Biomédicas, Universidad de Chile**
Tesis: "Direccionamiento de estímulo de los receptores 5-HT_{2A} y 5-HT_{2C} dirigido por derivados de anfetamina", profesor guía Dr. Bruce K. Cassels.
- 1993-1999 **Licenciado en Bioquímica, Universidad de Santiago de Chile**
Tesis: "Desarrollo de biopelículas de biosensores", profesor guía Dr. David S. Holmes.
- 1999 **Título Profesional de Bioquímico, Universidad de Santiago de Chile**

EXPERIENCIA LABORAL

- Sept 2013 - **Profesor Asociado (Jornada Completa, académico de Planta) Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso**
- 2011-2013 **Research Fellow, National Institute of Mental Health, NIH, Bethesda, MD, EEUU.**
- 2006-2011 **Postdoctorado, Laboratory of Clinical Science, NIMH/NIH, Bethesda, MD, EEUU.**

PARTICIPACION EN PROYECTOS DE INVESTIGACIÓN

- 2016 **Investigador Responsable.** FONIS "Evaluación de Polimorfismos como Biomarcadores de Resistencia Farmacológica en pacientes con Epilepsia del Policlínico de Neurología del Hospital Carlos Van Buren" N° SA16I0003 (2017-2018)
- 2016 **Co-Investigador.** FONDECYT Regular 1160398 "Neonatal programming: Sex hormones excess disrupts midbrain dopamine function in the adulthood" (2016-2019)
- 2016 **Investigador Adjunto.** Instituto Milenio Centro Interdisciplinario en Neurociencias de Valparaíso CINV, N° P09-022-F (2016-2020)
- 2014 **Investigador Responsable.** FONDECYT Regular 1141272 "GENERATION AND FUNCTIONAL CHARACTERIZATION OF MICE WITH ALTERED EXPRESSION OF EAAT3: A MODEL FOR OBSESSIVE-COMPULSIVE DISORDER" (2014-2017)
- 2014 **Director Alterno.** Núcleo Milenio Neurobiology of Neuropsychiatric Disorders NU-MIND, N° NC130011, Iniciativa Científica Milenio (2014-2016)

RESPONSABILIDADES ACADÉMICAS

- 2016 **Director,** Programa de Magister en Ciencias, Mención Neurología Molecular y Celular, Facultad de Ciencias y Facultad de Medicina, Universidad de Valparaíso (Res. Exenta 20.744).

Pablo R. Moya, PhD

2016 **Coordinador**, Unidad de Genómica, Convenio de Desempeño PMI-UVA1402 "Desarrollo de una Plataforma Interdisciplinaria para la Innovación en Salud: Un Referente Internacional en el Desarrollo de Medicina de Precisión" (Res. Exenta N° 21.062).

DIRECCION DE TESIS

Posgrado

- 2016-2017 "Evaluación De Cambios Moleculares Producidos Por La Sobre-Expresión Condicional De Eaat3 En Neuronas Piramidales De Ratonés". Marisol Cisternas Olmedo. Tesis para optar al grado de Magister en Biotecnología, Universidad Andrés Bello. Tutor, *Finalizada*.
- 2015-2017 "Evaluación de polimorfismos en genes *ABCB1* y *ABCC2* en pacientes con epilepsia refractaria del policlínico de neurológica del Hospital Carlos van Buren". Dr. Julio Riquelme; Tesis para optar al grado de Magister en Ciencias Biológicas mención Neurología Celular y Molecular, Universidad de Valparaíso. Tutor, *Finalizada*.
- 2016-2017 "Estudio de la distribución del transportador de glutamato EAAT3 en neuronas GABAérgicas y Glutamatergicas de cerebro de modelos murinos transgénicos". Isabel Gomez Silva; Tesis para optar al grado de Magister en Ciencias Médicas, Universidad de Valparaíso. Tutor, *Finalizada*.
- 2015-2017 "Rescate de la expresión del transportador de aminoácidos excitatorios Eaat3 en cerebro de ratones Knockout para el gen *Slc1a1*" Tomas Schwenke. Tesis para optar al grado de Magister en Biotecnología, Universidad Andrés Bello. Co-tutor, *Finalizada*.
- 2015- "Caracterización de conductas compulsivas en un modelo animal de Trastorno Obsesivo-Compulsivo". Tesis para optar al grado de Magister en Ciencias Médicas, Claudia Delgado, Universidad de Valparaíso. Tutor, *tesis en curso*.
- 2011-2014 "Estudio de la similitud de los sitios de unión de serotonina de la enzima monoaminoxidasa-A y el transportador de serotonina humanos mediante algoritmos matemáticos, simulación molecular y ensayos biológicos". Dr. Gabriel Nuñez-Vinanco; Tesis para optar al grado de Doctor en Biotecnología, USACH. Co-tutor. *Finalizada*.

Pregrado

- 2016-2017 "Evaluación De Cambios (Moleculares Y Neuroquímicos) Producidos Por La Sobre-Expresión Condicional De Eaat3 En Neuronas Gabaérgicas De Ratonés". Francisca Henríquez Belmar; Tesis para optar al título de Bioquímica, P. Universidad Católica de Valparaíso. Tutor, *Finalizada*.
- 2016-2017 "Caracterización neuroquímica en el circuito cortico-estriado-tálamo-cortical de un ratón con expresión deficiente de EAAT3: posible rol en el Trastorno Obsesivo-Compulsivo". Luis González Olivares. Tesis para optar al título de Químico Farmacéutico, Universidad de Valparaíso. Tutor, *Finalizada*.
- 2016- 2017 "Reutilización de fármacos para el tratamiento del trastorno Obsesivo-Compulsivo". Carlos Catalán Araya. Memoria para optar al título de Ingeniero en Bioinformática, Universidad de Talca. Tutor, *Finalizada*.

DOCENCIA

Pregrado

2014- Coordinador Curso Fisiopatología, carreras de Química y Farmacia, y Nutrición y Dietética Facultad de Farmacia, Universidad de Valparaíso.

Posgrado

- 2015- Coordinador Curso Troncal "Bases Biológicas de las Enfermedades Neuropsiquiátricas", Doctorado en Neurociencias, Universidad de Valparaíso.
- 2013- Coordinador Curso Electivo "Bases genéticas de las Enfermedades Neurológicas", Magister en Ciencias mención Neurología Celular y Molecular, Universidad de Valparaíso.

Pablo R. Moya, PhD

- 2013- Participación en Curso de posgrado "Neurofarmacología", Doctorado en Neurociencias y Magister en Neurociencias, Universidad de Valparaíso.
- 2013- Profesor participante en Curso Troncal de Neurociencias, Doctorado en Neurociencias. Módulos: "Control de la Expresión Génica", "Genética y Desarrollo del Sistema Nervioso" y "Control Motor y Conducta".

BECAS Y DISTINCIONES

- 2014 NIDA Travel Award, beca de asistencia al meeting de International Society for Serotonin Research, Cape Town, Sudáfrica
- 2011 NIMH Wang Service Award del National Institute of Mental Health, Bethesda, EEUU por servicios comunitarios destacados.
- 2008 Fellows Award for Research Excellence (FARE), National Institutes of Health, Bethesda EEUU. Premio para asistencia a congreso científico otorgado a investigaciones destacadas.
- 2004 The Serotonin Club Travel Award. Premio para asistencia al 4th meeting of Federation of European Pharmacological Societies EPHAR, Porto, Portugal.
- 2001 Beca de Doctorado del Instituto Milenio en Biología Celular y Biotecnología (CBB), Universidad de Chile (duración 4 años).

PUBLICACIONES

#: Autor correspondiente.

25. González LF, Henríquez-Belmar F, Delgado-Acevedo C, Cisternas-Olmedo M, Arriagada G, Sotomayor-Zárate R, Murphy DL, **#Moya PR**. (2017) "Neurochemical and behavioral characterization of neuronal glutamate transporter EAAT3 heterozygous mice" *Biol. Res.* 19;50(1):29. doi:10.1186/s40659-017-0138-3.
24. Ahumada C, Bahamondes C, Cerda CA, Silva RA, Cruz G, **Moya PR**, Sotomayor-Zárate R, Renard GM. (2017) "Amphetamine treatment affects the extra-hypothalamic vasopressinergic system in a sex- and nucleus-dependent manner" *J Neuroendocrinol.* Feb 24. doi: 10.1111/jne.12465
23. Muñoz P, Aschrafi A, **Moya PR** (2016) "Connecting Synaptic Activity with Plasticity-Related Gene Expression: From Molecular Mechanisms to Neurological Disorders," *Neural Plasticity*, vol. 2016:7149527. doi:10.1155/2016/7149527.
22. Espinosa P, Silva RA, Sanguinetti NK, Venegas FC, Riquelme R, González LF, Cruz G, Renard GM, **Moya PR**, Sotomayor-Zárate R. (2016) "Programming of Dopaminergic Neurons by Neonatal Sex Hormone Exposure: Effects on Dopamine Content and Tyrosine Hydroxylase Expression in Adult Male Rats" *Neural Plasticity*. Vol 2016:4569785. doi:10.1155/2016/4569785.
21. Sotomayor-Zárate R, Jara P, Araos P, Vinet R, Quiroz G, Renard GM, Espinosa P, Hurtado-Guzmán C, **Moya PR**, Iturriaga-Vásquez P, Gysling K, Reyes-Parada M (2014) "Improving amphetamine therapeutic selectivity: N,N-dimethyl-MTA has dopaminergic effects and does not produce aortic contraction" *Basic Clin Pharmacol Toxicol.* 114(5): 395-9. doi: 10.1111/bcpt.12168.
20. **#Moya PR**, Wendland JR, Andrews AM, Rubenstein L, Timpano KC, Heiman GA, Tischfield JA, King RA, Ramamoorthy S, McMahon F, Murphy DL (2013) "Common and rare alleles of the serotonin transporter gene, *SLC6A4*, associated with Tourette disorder" *Movement Disorders.* 28(9): 1263-70 DOI: 10.1002/mds.25460
19. Murphy DL, **Moya PR**, Fox MA, Rubenstein LM, Wendland JR, Timpano KR (2013) "Anxiety and Affective Disorder Comorbidity Related to Serotonin and other Neurotransmitter Systems: Obsessive-compulsive Disorder (OCD) as an Example of Overlapping Clinical and Genetic Heterogeneity" *Philosophical Transactions of the Royal Society B: Biological Sciences*, 368 (1615); Feb 25. DOI:10.1098/rstb.2012.0435 (REVIEW)
18. **#Moya PR**, Dodman NH, Timpano KC, Rubenstein L, Rana Z, Fried R, Tischfield JA, Heiman JA, King RA, Ginns E, Wendland JR (2013) "Neuronal Cadherin (*CDH2*) Gene Missense Variants in Specific Obsessive-Compulsive Disorder and Tourette Syndrome Phenotypes" *European Journal of Human Genetics*, 21(8): 850-4. DOI: 10.1038/ejhg.2012.245

17. **#Moya PR**, Wendland JR, Salemme J, Fried R, Murphy DL (2013) "miR15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells" *International Journal of Neuropsychopharmacology*, 16: 621–629.
16. Stewart SE, Mayerfeld C, Arnold PD, Crane JR, O'Dushlaine C, Fagerness JA, Scharf JM, Kassam F, **Moya PR**, Wendland JR, Delorme R, *et al.* (2013) "Meta-Analysis of association between obsessive-compulsive disorder and the 3' region of neuronal glutamate transporter gene *SLC1A1*" *American Journal of Medical Genetics part B: Neuropsychiatric Genetics*, 162: 367-379
15. Fox MA, Panessiti M, **Moya PR**, Tolliver TJ, Chen K, Shih JC, Murphy DL (2012) "Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin enhancing drugs: implications for drug side effects in humans" *The Pharmacogenomics Journal*, 13(6): 551-7. DOI: 10.1038/tj.2012.35.
14. Sotomayor-Zárate R, Quiroz G, Araya KA, Abarca J, Ibáñez MI, Montecinos A, Guajardo C, Núñez-Vicanco G, Fierro A, **Moya PR**, Iturriaga-Vásquez P, Gómez-Molina C, Gysling K, Reyes-Parada M (2012) "4-Methylthioamphetamine Increases Dopamine in the Rat Striatum and has Rewarding Effects In Vivo" *Basic and Clinical Pharmacology and Toxicology*, 111(6):371-9. DOI: 10.1111/j.1742-7843.2012.00926.x.
13. Khaibullina A, Kenyon N, Guptill V, Quezado M, Koziol D, Wesley R, **Moya PR**, Zhang Z, Saha A, Mukherjee AB, Quezado ZMN (2012) "In a model of Batten disease, palmitoyl protein thioesterase-1 deficiency is associated with brown adipose tissue and thermoregulation abnormalities" *PLoS One*, 7(11):e48733.
12. Liu X, Cannon DM, Akula N, **Moya PR**, Knudsen GM, Arentzen TE, Steele J, Laje G, Drevets WC, McMahon FJ (2011) "A non-synonymous polymorphism in galactose mutarotase (*GALM*) is associated with serotonin transporter binding potential in the human thalamus: results of a genome-wide association study" *Molecular Psychiatry* 16(6):584-5.
11. Murphy DL and **Moya PR** (2011) "Human Serotonin Transporter Gene (*SLC6A4*) variants: Their contributions to understanding pharmacogenomic and other functional G x G and G x E differences in health and disease" *Current Opinions in Pharmacology*, 11(1):3-10.
10. **#Moya PR**, Jensen CL, Fox MA, French H, Wendland JR and Murphy DL (2011) "Altered 5-HT_{2C} receptor agonist-induced responses and 5-HT_{2C} receptor RNA editing in the amygdala of serotonin transporter knockout mice" *BMC (BioMed Central) Pharmacology* 11:3.
9. **#Moya PR**, Murphy DL, McMahon FJ and Wendland JR (2010) "Increased gene expression of Diacylglycerol Kinase Eta in Bipolar Disorder" *International Journal of Neuropsychopharmacology* 13(8):1127-1128
8. Omata N, Chiu CT, **Moya PR**, Leng Y, Chiu C, Wang Z, Hunsberger J, Leeds P, Chuang DM (2011) "Lentivirally mediated GSK-3 β silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice " *International Journal of Neuropsychopharmacology* 14(5):711-717
7. Wendland JR, **Moya PR**, Timpano K, Anavitarte A, Kruse M, Wheaton M, Ren-Patterson R, Murphy DL (2009) "A haplotype containing quantitative trait loci for *SLC1A1* gene expression is associated with obsessive-compulsive disorder" *Archives of General Psychiatry* 66(4):408-16.
6. **(* first co-author)** Wendland JR*, **Moya PR***, Kruse MR, Ren-Patterson RF, Jensen CL, Timpano KR and Murphy DL (2008) "A novel, putative gain-of-function haplotype at *SLC6A4* associates with obsessive-compulsive disorder" *Human Molecular Genetics* 17(5):717-23.
5. Murphy, DL, Fox MA, Timpano KR, **Moya PR**, Ren-Patterson R, Andrews A, Holmes, A, Wendland JR, Lesch KP (2008) "How the serotonin story is being rewritten by new gene-based discoveries principally related to *SLC6A4*, the serotonin transporter gene, whose functions influence the entire serotonin system" *Neuropharmacology* 55:932-960.
4. Gobbi M, Funicello M, Gerstbrein K, Holy M, **Moya PR**, Sotomayor R, Forray MI, Gysling K, Paluzzi S, Bonanno G, Reyes-Parada M, Sitte HH, Mennini T (2008) "N,N-dimethyl-thioamphetamine and methylthioamphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant in vitro efficacy for the induction of transporter-mediated 5-HT release and currents" *Journal of Neurochemistry* 105(5):1770-80.

Pablo R. Moya, PhD

3. **Moya PR**, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (2007) "Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-HT_{2A} and 5-HT_{2C} Receptors" *Journal of Pharmacology and Experimental Therapeutics* 321(3):1054-61.
2. Valdecantos P, Briones R, **Moya P**, Germain A, and Huidobro-Toro JP (2003) "Pharmacological identification of P_{2X}(1), P_{2X}(4) and P_{2X}(7) nucleotide receptors in the smooth muscles of human umbilical cord and chorionic blood vessels" *Placenta* 24(1):17-26.
1. Acuña-Castillo C, Villalobos C, **Moya PR**, Sáez P, Cassels BK, and Huidobro-Toro JP (2002) "Differences in potency and efficacy of a series of phenylisopropylamine / phenylethylamine pairs at 5-HT_{2A} and 5-HT_{2C} receptors" *British Journal of Pharmacology* 136: 510-519.

CAPÍTULOS DE LIBROS:

Murphy DL, **Moya PR**, Wendland JR and Timpano KR (2012) "Genetic contributions to obsessive-compulsive disorder (OCD) and OCD-related disorders", en *Principles of Psychiatric Genetics*, J. Nurnberger & W. Berrettini Eds, Cambridge University Press, Cambridge, UK. Capítulo 11, pp 121-133. ISBN: 0521896495.

CONFERENCIAS, SEMINARIOS Y PRESENTACIONES ORALES

- Oct 2016 "Transgenic Mouse Overexpressing Eaat3 (Neuronal Glutamate Transporter): A Novel Genetic Model of Obsessive-Compulsive Disorder" Oral presentation at XXIV World Congress of Psychiatric Genetics, Jerusalem, Israel.
- Oct 2016 "Polymorphisms in *ABCB1* and *ABCC2* genes in patients with Drug-Resistant Epilepsy at Van Buren Hospital in Valparaíso, Chile". Oral presentation at 2nd International Conference on Epilepsy and Treatment, Rome, Italy.
- Julio 2014 "Common and rare gain-of-function alleles of the serotonin transporter gene, *SLC6A4*, associated with Tourette disorder" Oral presentation at The International Society for Serotonin Research Meeting, Arabella, South Africa.
- Nov, 2012 "Rare and common gain-of-function alleles of the serotonin transporter gene, *SLC6A4*, associated with Tourette disorder", en sesión: "Neuropsychiatric Disorders"; *62 Annual Meeting of American Society of Human Genetics (ASHG)*, San Francisco, CA, EEUU. (Abstract # 261)
- Nov 2012 "Regulación de la expresión del transportador de serotonina: variantes humanas y su rol en neuropsiquiatría", en simposio "Neurofarmacología de transportadores de monoaminas: del modelamiento molecular a la conducta"; XXXIV reunión de la Sociedad de Farmacología de Chile, Pucón, Chile.
- Oct, 2012 "Functional variants in the serotonin transporter gene (*SLC6A4*) associated with Tourette syndrome", en nanosimposio: "ADHD, SLI, Dyslexia and Other Specific Disorders of Neurobehavior"; reunion anual de la Society for Neuroscience, New Orleans, LA, EEUU. (Abstract # 122.06)
- Marzo, 2011 "Serotonina y Glutamato en Trastorno Obsesivo-Compulsivo", Conferencia internacional, Research Retreat de la Escuela de Medicina, Universidad Austral, Valdivia, Chile.
- Marzo, 2011 "Neurogenética de Trastornos de Ansiedad", Conferencia inaugural del Programa de Doctorado en Neurociencias, Facultad de Química y Biología, Universidad de Santiago de Chile; Santiago, Chile.
- March, 2011 "Genética de *SLC6A4* and *SLC1A1* en el Trastorno Obsesivo-Compulsivo", Ciclos de seminarios del Núcleo Milenio en Estrés y Adicción NEDA, Pontificia Universidad Católica; Santiago, Chile.

Pablo R. Moya, PhD

- Sept, 2008 "Altered RNA editing of the serotonin 2C receptor in the amygdala of mice with targeted deletion of the serotonin transporter", 12th NIMH Intramural Research Program (DIRP) Scientific Retreat, Gettysburg, PA, EEUU.
- Julio 2004 "Hallucinogenic amphetamines and phenethylamines have different pharmacological profiles: *in vitro* and *in vivo* studies" en reunion satélite de The Serotonin Club (International Society for Serotonin Research), 4th meeting of Federation of European Pharmacological Societies EPHAR, Porto, Portugal. *Fundamental and Clinical Pharmacology* 2004, S1, 145.

PRESENTACIONES EN FORMATO PANEL EN REUNIONES CIENTÍFICAS

- 2015 Delgado C, Martínez J, Henríquez F., González, LF., **Moya, PR**. "Evaluation of Obsessive Compulsive Disorder- related behaviors in a mouse model with altered Eaat3 expression in GABAergic neurons" *Meeting de la Sociedad Chilena de Neurociencia*, Coquimbo 22-25 Septiembre, Chile.
- 2015 Martínez J, Riquelme J, Saldias C, Rodríguez, L, **Moya, PR**. "Polymorphisms in *ABCB1* and *ABCC2* genes in patients with Drug-Resistant Epilepsy at Van Buren Hospital in Valparaíso, Chile". *Sociedad Chilena de Neurociencia*, Coquimbo 22-25 Septiembre, Chile.
- 2015 González, LF, Espinosa, P, Sotomayor-Zárate, R, **Moya, PR** "Neurochemical characterization in cortico-striatal-thalamo-cortical circuit of Eaat3 heterozygous mice: role in neuropsychiatric disorders". *Sociedad Chilena de Neurociencia*, Coquimbo 22-25 Septiembre, Chile.
- 2015 **Moya, PR**, Utreras E, Martínez J. "Generation of a novel genetic mouse model for Obsessive-Compulsive Disorder". *Sociedad Chilena de Neurociencia*, Coquimbo 22-25 Septiembre, Chile.
- 2015 Riquelme J, Saldias C, Martinez J, **Moya PR** "Polymorphisms in *ABCB1* and *ABCC2* Genes In Patients With Drug-Resistant Epilepsy At Van Buren Hospital In Valparaíso, Chile". *XXII World Congress of Neurology (WCN)*, Santiago, Chile 31 Oct – 5 Nov, 2015.
- 2014 **Pablo R. Moya**, Jens R. Wendland, Ashok Kulkarni and Dennis L. Murphy. "Generation of transgenic mice with altered EAAT3 expression: a putative animal model of Obsessive-Compulsive Disorder". 17th World Congress of Basic and Clinical Pharmacology, Cape Town, South Africa 13-18 July.
- 2012 **Moya PR**, Wendland JR, Andrews AM, Rubenstein LM, Timpano KR, Heiman GA, Tischfield JA, King RA, Ramamoorthy S, McMahon FJ and Murphy DL "Common and rare gain-of-function alleles of the serotonin transporter gene *SLC6A4* associated with Tourette disorder" *Meeting of the American College of Neuropsychopharmacology (ACNP)*, Hollywood, FL, EEUU. (Abstract #Tue-17).
- 2012 Fox MA, **Moya PR**, Sotomayor-Zarate R., Iturriaga-Vasquez P., Hall FS, Chen K, Shih JC, Uhl GR, Reyes-Parada M, Murphy DL "An examination of involvement of the dopamine transporter (DAT), the serotonin transporter (SERT) and monoamine oxidase A (MAOA) in the temperature and locomotor effects of 4-methylthioamphetamine (MTA)" *Meeting of the American College of Neuropsychopharmacology (ACNP)*, Hollywood, FL, EEUU. (abstract # Mon-150)
- 2011 **Moya PR**, Wendland JR, Timpano KC, Rubenstein L, Rana Z, Fried R, Galdzicka M, Ginns E, Dodman NH and Murphy DL (2011) "CDH2 gene variants in Obsessive Compulsive Disorder and Tourette Syndrome" *Meeting of the American College of Neuropsychopharmacology (ACNP)*, Waikoloa, HI, EEUU. (Abstract # Tue-104)
- 2010 **Moya PR**, Reyes-Parada M, Iturriaga-Vasquez P, Fierro A, Nunez G, and Murphy, DL "Determining the Binding Mode of Amphetamine Derivatives at the Serotonin Transporter" *Meeting of the American College of Neuropsychopharmacology (ACNP)*, Miami, FL, EEUU.

Pablo R. Moya, PhD

- 2010 **Moya PR**, Reyes-Parada M, Iturriaga-Vasquez P, Fierro A, Nunez G, Vilches-Herrera M and Murphy DL (2010) "Initial Binding Interactions of Amphetamine Derivatives at the Serotonin Transporter" *Society For Neuroscience Meeting*, San Diego, CA, EEUU.
- 2009 **Moya PR**, Saleme J and Murphy DL (2009) "Enhanced antidepressant-like effect of Lithium in Serotonin Transporter Knockout mice" *Meeting of the American College of Neuropsychopharmacology (ACNP)*, Hollywood, FL, EEUU.(Abstract Tue-98)
- 2009 **Moya PR**, Murphy DL, McMahon FJ, and Wendland JR (2009) "Increased gene expression of Diacylglycerol Kinase Eta in Bipolar Disorder" *Society For Neuroscience Meeting*, Chicago, IL. (Abstract # 745.22/U15)
- 2009 **Moya PR**, Fox MA, Laporte J, Jensen C, Wendland JR and Murphy D L (2009)"Altered responsiveness of Htr2c in the amygdala of 5-HT transporter knockout mice" *Gordon Research Conference "Amygdala In Health & Disease"*, Colby College, Waterville, ME, EEUU.
- 2009 **Moya PR**, Laporte J, Wendland JR, Jensen, C, Anavitarte A and Murphy DL (2009) "Regulation of human serotonin transporter expression by microRNAs (miRNAs)" *18th meeting of the International Behavioural Neuroscience Society (IBNS)*, Nassau, Bahamas.
- 2008 **Moya PR**, Wendland JR, Jensen C, Anavitarte A and Murphy DL (2008) "Regulation of human serotonin transporter expression by microRNAs" *Meeting of the American College of Neuropsychopharmacology (ACNP)*, Scottsdale, AZ, EEUU. (Abstract Mon-167)
- 2008 **Moya PR**, Wendland JR, Murphy DL "Regulation of human serotonin transporter by microRNAs" *Society For Neuroscience Meeting*, Washington, DC, EEUU. (abstract 256.12/Z15)
- 2007 **Moya PR**, Fox MA, Jensen C, Wendland JR, Jacobowitz D and Murphy DL (2007) "Targeted deletion of the serotonin transporter alters the RNA editing pattern of the serotonin 2C receptor in amygdala of mice" *Meeting of the American College of Neuropsychopharmacology (ACNP)*, Boca Raton, FL, EEUU.(Abstract Wed-165).
- 2007 Wendland JR, Kruse MR, Cromer KR, **Moya PR**, Wheaton M, Murphy DL. "Quantitative Trait Loci for SLC1A1 Gene Expression Are Associated with Obsessive-Compulsive Disorder, *Meeting of the American College of Neuropsychopharmacology (ACNP)*, Boca Raton, FL, EEUU (Abstract Tue-77).
- 2007 **Moya PR**, Jensen C, Wendland JR, Fox MA, D and Murphy DL "Altered RNA editing of the serotonin 2C receptor (Htr2c) receptor in the amygdala of mice with targeted deletion of the serotonin transporter" *Society For Neuroscience Meeting*, San Diego, CA, EEUU.(Abstract 269.10/X6)
- 2003 Sotomayor R., **Moya P.**, Reyes-Parada M., Hurtado-Guzman C, Iturriaga-Vasquez P., Forray M.I., Gysling K. "p-Metiltioamfetamina y sus derivados N-metilados inducen la liberación de 5-HT en septum lateral de rata". Congreso de la Sociedad de Farmacología de Chile, Tome, Chile, Noviembre 2003.
- 2000 **Moya P.R.**, Huidobro-Toro J. "Detección de mRNA`s para receptores P2X en arterias coriónicas humanas"; Primer Encuentro Argentino-Chileno de Farmacología y Reunión anual de la Sociedad de